Evaluation of therapy for canine intracranial neoplasia using PAC-1, a novel and potent procaspase-3 activator

Schlein, Lisa Janelle

Permalink

https://hdl.handle.net/2142/99088 Copy

Description

Title

Evaluation of therapy for canine intracranial neoplasia using PAC-1, a novel and potent procaspase-3 activator

Author(s)

Schlein, Lisa Janelle

Issue Date

2017-07-14

Director of Research (if dissertation) or Advisor (if thesis)

Fan, Timothy M.

Committee Member(s)

• Driskell, Elizabeth
• Barger, Anne
• Hergenrother, Paul

Department of Study

Pathobiology

Discipline

VMS - Pathobiology

Degree Granting Institution

University of Illinois at Urbana-Champaign

Degree Name

M.S.

Degree Level

Thesis

Keyword(s)

• Cancer
• Brain cancer
• Intracranial neoplasia
• Canine neoplasia
• Human neoplasia
• Novel therapeutics
• First procaspase-activating compound (PAC-1)

Abstract

Canine central nervous system tumors can develop deeply within the brain parenchyma, precluding surgical resection and limiting therapeutic options. PAC-1 is a novel, blood-brain barrier penetrant, pro-apoptotic small molecule activator of procaspase-3 (PC-3), with orphan drug status for the treatment of human glioblastoma multiforme. PC-3 is frequently overexpressed in malignantly transformed tissues, providing an opportunity to selectively induce apoptosis in cancer cells with dysregulated upstream apoptotic circuitry. This study evaluates the in vitro activity of PAC-1 against a panel of brain tumor cells, and the feasibility of combining PAC-1 with radiation therapy in an in vivo murine glioma model. Immunohistochemical characterization of PC-3 was performed in 21 normal canine brains and approximately 700 canine and human intracranial neoplasms. Murine, canine, and human glioma cell lines were evaluated for PC-3 expression and in vitro sensitivity to PAC-1 and radiation. PC-3 is overexpressed in canine intracranial neoplasms and high-grade human astrocytomas relative to normal brain tissues. Immortalized glioma cell lines show in vitro sensitivity to PAC-1 and radiation monotherapies at biologically relevant exposures. Murine gliomas appear to be sensitive to PAC-1 and radiation monotherapies, as well as to combination therapy with both PAC-1 and radiation therapy; however, murine study results are not statistically significant at this time. Investigation of therapeutic approaches that combine PAC-1 with radiation therapy and/or temozolomide will further elucidate its therapeutic potential in murine models and canine patients.

Graduation Semester

2017-08

Type of Resource

text

Permalink

http://hdl.handle.net/2142/99088

Copyright and License Information

Copyright 2017 Lisa J. Schlein

Owning Collections